Headlines about BioCryst Pharmaceuticals (NASDAQ:BCRX) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioCryst Pharmaceuticals earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.7055947203557 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news headlines that may have impacted Accern’s rankings:

BioCryst Pharmaceuticals (BCRX) opened at $4.68 on Monday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.54 and a current ratio of 1.57. BioCryst Pharmaceuticals has a 12-month low of $3.75 and a 12-month high of $9.25.

BCRX has been the subject of several recent research reports. Jefferies Group LLC upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $5.00 to $7.00 in a research note on Wednesday, September 6th. ValuEngine lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 3rd. J P Morgan Chase & Co upgraded shares of BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $6.00 to $9.00 in a research report on Tuesday, September 5th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, September 6th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $8.78.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/biocryst-pharmaceuticals-bcrx-earning-somewhat-positive-news-coverage-study-shows/1682439.html.

In related news, Director Fred E. Cohen sold 54,250 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $5.42, for a total value of $294,035.00. Following the completion of the sale, the director now owns 173,660 shares of the company’s stock, valued at $941,237.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.60% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Insider Buying and Selling by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.